在病毒样颗粒上显示的嵌合蛋白的设计和结构特征,用于针对沙门氏菌Typhi的向免疫激活
Saghi Nooraei1, Abbas Hajizade2, Hossein Tarrahimofrad3
1Department of System Biotechnology, National Institute of Genetic Engineering and Biotechnology (NIGEB), P. O. BOX: 14155-6343, Tehran, 1497716316, Iran.
International journal of biological macromolecules
|February 17, 2026
概括
一种在病毒样颗粒 (VLPs) 上显示沙门氏菌Typhi表位的新型嵌合蛋白在小鼠中证明了100%的生存率. 这种工程巨分子平台显示了先进的传染病治疗方法的前景.
科学领域:
- * 生物技术和蛋白质工程
- * 疫苗开发和免疫学
- * 分子建模和模拟
背景情况:
- * 沙门氏菌 (S. typhi) 构成严重的全球健康威胁,需要创新的治疗策略.
- *目前的治疗方法面临挑战,推动研究新型疫苗平台.
- * 对抗伤寒热的有效疫苗的需求仍然至关重要.
研究的目的:
- * 设计一个使用病毒样颗粒 (VLP) 的宏分子平台,显示沙门氏菌类型的仿真抗原 (OFFS-ST).
- * 评估工程化化学蛋白对伤寒的免疫性和保护功效.
- * 调查SpyCatcher/SpyTag结合的潜力,以创建稳定的抗原显示VLP.
主要方法:
- *使用SpyCatcher/SpyTag系统构建一个整合S. Typhi表位体 (OmpC,OmpF,flagellin) 的重组化学蛋白.
- * 在AP205病毒样颗粒 (VLPs) 上显示化基蛋白.
- *通过抗体测定,细胞因子分析,挑战测试和分子动力学模拟评估BALB/c小鼠的免疫反应.
主要成果:
- * 在VLP上成功结合和化学蛋白的结构完整性得到证实.
- *分子动力学模拟表明与TLR5的良好相互作用,表明Th1/Th2免疫刺激的潜力.
- *VLP显示的奇米蛋白 (NanosalVAX) 配方在小鼠中实现了100%的生存率,对抗致命的S. Typhi挑战,与单独的奇米蛋白不同.
结论:
- * 工程化宏分子,特别是VLP上显示的嵌合蛋白,代表了针对S. Typhi.疫苗开发的有希望的平台.
- * NanosalVAX配方引起了强大的保护性免疫力,突显了基于VLP的疫苗的潜力.
- *这项研究强调了先进的蛋白质工程和VLP技术在对抗伤寒等传染病方面的有效性.
更多相关视频
12:53Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development
Published on: March 16, 2022
2.2K
08:07A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
Published on: July 25, 2022
3.1K
相关概念视频
00:56Viral Structure
Viruses are extraordinarily diverse in shape and size, but they all have several structural features in common. All viruses have a core that contains a DNA- or RNA-based genome. The core is surrounded by a protective coat of proteins called the capsid. The capsid is composed of subunits called capsomeres. The capsid and genome-containing core are together known as the nucleocapsid.
01:10Antibody Structure
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
01:10Antibody Structure
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...